CORT Corcept Therapeutics Incorporated Stock Quote

CORT [NASD]

Index	-	P/E	26.67	EPS (ttm)	0.77	Insider Own	0.30%	Shs Outstand	116.29M	Perf Week	-2.80%
Market Cap	2.39B	Forward P/E	20.99	EPS next Y	0.98	Insider Trans	-9.70%	Shs Float	104.42M	Perf Month	0.84%
Income	97.60M	PEG	-	EPS next Q	0.20	Inst Own	71.60%	Short Float	7.96%	Perf Quarter	-8.84%
Sales	343.10M	P/S	6.96	EPS this Y	11.10%	Inst Trans	-1.34%	Short Ratio	16.14	Perf Half Y	-19.95%
Book/sh	4.49	P/B	4.57	EPS next Y	19.15%	ROA	17.50%	Target Price	25.25	Perf Year	19.14%
Cash/sh	3.18	P/C	6.45	EPS next 5Y	-	ROE	19.10%	52W Range	16.42 - 31.18	Perf YTD	-21.60%
Dividend	-	P/FCF	17.82	EPS past 5Y	74.60%	ROI	19.60%	52W High	-34.22%	Beta	0.71
Dividend %	-	Quick Ratio	9.00	Sales past 5Y	47.70%	Gross Margin	98.50%	52W Low	24.91%	ATR	0.43
Employees	236	Current Ratio	9.10	Sales Q/Q	3.40%	Oper. Margin	31.10%	RSI (14)	40.04	Volatility	2.15% 1.96%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-8.90%	Profit Margin	28.40%	Rel Volume	3.86	Prev Close	20.63
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Jul 29 AMC	Payout	0.00%	Avg Volume	514.81K	Price	20.51
Recom	2.50	SMA20	-2.80%	SMA50	-2.11%	SMA200	-13.23%	Volume	1,988,895	Change	-0.58%

Aug-05-20

Downgrade

Jefferies

Buy → Hold

$16

Sep-24-19

Initiated

Jefferies

Buy

$20

Sep-06-19

Initiated

H.C. Wainwright

Buy

$18

Feb-04-19

Downgrade

B. Riley FBR

Buy → Neutral

$22 → $12

Aug-10-18

Reiterated

Stifel

Hold

$20 → $11

May-31-18

Downgrade

Stifel

Buy → Hold

$20

Mar-09-18

Initiated

B. Riley FBR, Inc.

Buy

$30

Aug-31-17

Initiated

Stifel

Buy

$20

Feb-02-17

Initiated

Ladenburg Thalmann

Buy

$14

Apr-21-15

Initiated

FBR Capital

Outperform

$12

Jan-13-14

Downgrade

Stifel

Buy → Hold

Aug-09-13

Downgrade

Ladenburg Thalmann

Buy → Neutral

$3.30

Aug-09-13

Downgrade

Janney

Buy → Neutral

Feb-21-12

Reiterated

JMP Securities

Mkt Outperform

$9 → $11

Jan-06-10

Upgrade

Ladenburg Thalmann

Neutral → Buy

Jul-17-08

Initiated

Rodman & Renshaw

Mkt Outperform

Jun-21-07

Upgrade

Punk, Ziegel & Co

Mkt Perform → Accumulate

Sep-17-21 10:53AM	Corcept Therapeutics' Relacorilant Combo Therapy Shows Clinical Benefit In Ovarian Cancer Benzinga
08:30AM	Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer GlobeNewswire
Sep-16-21 11:26AM	Chief Business Officer Of Corcept Therapeutics Makes $1.13 Million Sale Benzinga
Sep-09-21 04:05PM	Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021 GlobeNewswire
Sep-08-21 07:00AM	SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm GlobeNewswire
Aug-12-21 05:00PM	William Guyer to join Corcept as Chief Development Officer GlobeNewswire
Jul-30-21 01:33PM	Corcept's (CORT) Q2 Earnings Beat Estimates, Revenues Rise Y/Y Zacks
04:32AM	Corcept Therapeutics Incorporated (CORT) Q2 2021 Earnings Call Transcript Motley Fool
Jul-29-21 06:35PM	Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates Zacks
04:05PM	Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update GlobeNewswire
Jul-27-21 11:40AM	CORT or ZTS: Which Is the Better Value Stock Right Now? Zacks
Jul-23-21 02:29AM	Is Corcept Therapeutics Incorporated's (NASDAQ:CORT) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
Jul-22-21 04:05PM	Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call GlobeNewswire
Jul-15-21 10:43AM	Lilly's (LLY) Protomer Acquisition to Expand Diabetes Pipeline Zacks
Jul-12-21 08:30AM	Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications Officer GlobeNewswire
Jun-22-21 10:36AM	Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer Benzinga
08:30AM	Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer GlobeNewswire
Jun-17-21 02:53AM	Are Insiders Buying Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock? Simply Wall St.
Jun-16-21 05:00AM	SHAREHOLDER ALERT: Barr Law Group Investigating CORT, SEMMX, MSEIX, and MIMFX; Shareholders are Encouraged to Contact the Firm GlobeNewswire
Jun-15-21 08:30AM	Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical GlobeNewswire
Jun-10-21 07:30AM	Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors GlobeNewswire
May-14-21 09:15AM	Corcept's (CORT) Lead Drug Korlym Aids Growth Amid Competition Zacks
May-07-21 12:17PM	Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1 Zacks
10:09AM	Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y Zacks
06:56AM	Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients Benzinga
06:31AM	Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call Transcript Motley Fool
May-06-21 05:20PM	Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates Zacks
04:10PM	Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results GlobeNewswire
04:05PM	Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH) GlobeNewswire
04:01PM	Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer GlobeNewswire
02:45PM	Corcept Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-05-21 06:32AM	Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy? Zacks
Apr-29-21 04:05PM	Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call GlobeNewswire
Apr-26-21 12:31PM	Earnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to Decline Zacks
Apr-05-21 02:42AM	Imagine Holding Corcept Therapeutics (NASDAQ:CORT) Shares While The Price Zoomed 398% Higher Simply Wall St.
Mar-25-21 11:30AM	Why Is Corcept (CORT) Down 11.1% Since Last Earnings Report? Zacks
Mar-24-21 06:12AM	3 Healthcare Stocks That Could Be Millionaire-Makers Motley Fool -5.89%
Mar-16-21 09:34AM	Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant Zacks
Mar-15-21 07:30AM	Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess GlobeNewswire
Mar-01-21 04:05PM	Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer GlobeNewswire
Feb-23-21 04:05PM	Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results GlobeNewswire
Feb-19-21 01:26AM	Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals? Simply Wall St.
Feb-14-21 01:32PM	15 Best Small-Cap Healthcare Stocks to Buy Insider Monkey
Feb-10-21 11:40AM	AMRX or CORT: Which Is the Better Value Stock Right Now? Zacks
Feb-09-21 09:54AM	Corcept (CORT) Posts Preliminary '20 Results, Gives 2021 View Zacks
Feb-08-21 11:00PM	Corcept Therapeutics Incorporated (CORT) Q4 2020 Earnings Call Transcript Motley Fool
04:05PM	Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update GlobeNewswire
03:15PM	Corcept Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-05-21 08:36AM	Why Corcept Therapeutics (CORT) Might Surprise This Earnings Season Zacks
Feb-01-21 04:05PM	Corcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call GlobeNewswire
Jan-20-21 12:05AM	Here's What Corcept Therapeutics Incorporated's (NASDAQ:CORT) Shareholder Ownership Structure Looks Like Simply Wall St.
Dec-31-20 09:40AM	Corcept (CORT) Up More Than 50% in Past 3 Months: Here's Why Zacks
Dec-21-20 12:20AM	What Can We Make Of Corcept Therapeutics' (NASDAQ:CORT) CEO Compensation? Simply Wall St.
Dec-19-20 06:23PM	Is CORT A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-03-20 11:30AM	Why Is Corcept (CORT) Up 25.8% Since Last Earnings Report? Zacks
Nov-23-20 05:00PM	Corcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of Directors GlobeNewswire
Nov-18-20 05:40PM	U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcepts U.S. Patent No.10,195,214 GlobeNewswire
Nov-13-20 05:36AM	George Baker Is The Independent Director of Corcept Therapeutics Incorporated (NASDAQ:CORT) And Just Spent US$243k On Shares Simply Wall St.
Nov-05-20 10:53AM	New Strong Sell Stocks for November 5th Zacks
Nov-04-20 12:08PM	Corcept (CORT) Misses on Q3 Earnings, Tightens 2020 Sales View Zacks
Nov-03-20 05:15PM	Corcept Therapeutics (CORT) Lags Q3 Earnings and Revenue Estimates Zacks
04:29PM	Corcept Therapeutics: Q3 Earnings Insights Benzinga
04:05PM	Corcept Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
03:15PM	Corcept Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Oct-27-20 04:05PM	Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call GlobeNewswire
Oct-16-20 08:00AM	Here's Why I Think Corcept Therapeutics (NASDAQ:CORT) Is An Interesting Stock Simply Wall St.
Oct-07-20 10:26AM	Why Corcept Therapeutics Soared 37% Higher in September Motley Fool
Oct-05-20 12:46PM	Hedge Funds Have Never Been This Bullish On Corcept Therapeutics Incorporated (CORT) Insider Monkey
Sep-29-20 09:00AM	SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of Corcept Therapeutics Incorporated (CORT) and Encourages Long-Term CORT Stockholders to Contact the Firm PR Newswire
Sep-24-20 07:10AM	2 Monster Stocks in the Making Motley Fool
Sep-18-20 07:26AM	Corcept Therapeutics Incorporated's (NASDAQ:CORT) Shares Climb 26% But Its Business Is Yet to Catch Up Simply Wall St.
Sep-17-20 10:56AM	Corcept's Lead Drug Korlym Aids Growth, Heavy Reliance a Woe Zacks
Sep-10-20 08:30AM	Corcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant to Treat Weight Gain Caused by Antipsychotic Medication GlobeNewswire -8.02%
Sep-08-20 04:34AM	BiohavenPharmaHldg Reaches 80-Plus Relative Strength Rating Benchmark Investor's Business Daily -8.08%
Sep-04-20 11:41AM	Stocks To Watch: Arena Pharmaceuticals Sees Relative Strength Rating Rise To 83 Investor's Business Daily
07:04AM	Corcept Therapeutics Incorporated's (NASDAQ:CORT) Shares May Have Run Too Fast Too Soon Simply Wall St.
Sep-03-20 11:31AM	Why Is Corcept (CORT) Up 38.4% Since Last Earnings Report? Zacks
09:50AM	Looking Into Corcept Therapeutics's Return On Capital Employed Benzinga
08:44AM	Is the Options Market Predicting a Spike in Corcept Therapeutics (CORT) Stock? Zacks
06:31AM	Trade Alert: The Independent Director Of Corcept Therapeutics Incorporated (NASDAQ:CORT), George Baker, Has Just Spent US$578k Buying A Few More Shares Simply Wall St.
Sep-01-20 09:34AM	Is Corcept Therapeutics Incorporated (NASDAQ:CORT) Trading At A 35% Discount? Simply Wall St.
Aug-05-20 05:56PM	Shuman Glenn & Stecker Investigates Corcept Therapeutics, Inc. Business Wire -8.48%
02:11PM	Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark Zacks
02:01AM	Corcept Therapeutics Incorporated (CORT) Q2 2020 Earnings Call Transcript Motley Fool
Aug-04-20 04:05PM	Corcept Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Aug-03-20 06:27PM	Composite Rating For Emergent Biosolutions Rises To 99 Investor's Business Daily
01:00PM	Did Hedge Funds Make The Right Call On Corcept Therapeutics Incorporated (CORT) ? Insider Monkey
11:26AM	What Kind Of Investors Own Most Of Corcept Therapeutics Incorporated (NASDAQ:CORT)? Simply Wall St.
Jul-28-20 04:05PM	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call GlobeNewswire
08:30AM	Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushings Syndrome of Adrenal Origin GlobeNewswire
Jul-23-20 08:30AM	Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian Cancer GlobeNewswire
Jul-21-20 07:08PM	New GuruFocus Feature: Warren Buffett's Baskets GuruFocus.com
Jul-07-20 10:00AM	These 3 Biotech Stocks Are Outperforming Their Peers Here's Why Investor's Business Daily
Jul-06-20 12:56PM	Is Corcept Therapeutics Incorporated's(NASDAQ:CORT) Recent Stock Performance Tethered To Its Strong Fundamentals? Simply Wall St.
Jul-01-20 10:47AM	Corcept Begins Enrollment in Phase III Pancreatic Cancer Study Zacks
Jun-30-20 04:05PM	Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer GlobeNewswire
Jun-19-20 09:40AM	Hedge Funds Standing By Corcept Therapeutics Incorporated (CORT) Insider Monkey
Jun-15-20 08:30AM	Corcept Therapeutics to Present Data at the American Association of Cancer Research Annual Meeting GlobeNewswire
Jun-08-20 11:24PM	Edited Transcript of CORT earnings conference call or presentation 4-May-20 9:00pm GMT Thomson Reuters StreetEvents
Jun-03-20 11:30AM	Why Is Corcept (CORT) Up 8.2% Since Last Earnings Report? Zacks

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Robb Gary Charles	Chief Business Officer	Sep 15	Sale	20.49	47,853	980,742	87,848	Sep 15 06:13 PM
Robb Gary Charles	Chief Business Officer	Sep 14	Sale	20.76	806	16,736	135,701	Sep 15 06:13 PM
Robb Gary Charles	Chief Business Officer	Sep 13	Sale	20.89	6,341	132,445	136,507	Sep 15 06:13 PM
Swisher Daniel N JR	Director	Sep 02	Option Exercise	6.55	7,500	49,125	7,500	Sep 03 05:30 PM
Swisher Daniel N JR	Director	Sep 02	Sale	21.70	7,500	162,741	0	Sep 03 05:30 PM
Maduck Sean	Chief Commercial Officer	Sep 01	Option Exercise	3.29	25,000	82,250	65,024	Sep 03 05:10 PM
Maduck Sean	Chief Commercial Officer	Sep 01	Sale	21.40	25,000	534,930	40,024	Sep 03 05:10 PM
Robb Gary Charles	Chief Business Officer	Aug 30	Option Exercise	2.70	148,148	400,000	223,786	Sep 01 05:36 PM
Maduck Sean	Chief Commercial Officer	Aug 03	Option Exercise	3.29	25,000	82,250	65,024	Aug 05 05:30 PM
Maduck Sean	Chief Commercial Officer	Aug 03	Sale	21.18	25,000	529,420	40,024	Aug 05 05:30 PM
Hunt Hazel	Chief Scientific Officer	Jul 14	Option Exercise	2.89	50,000	144,500	68,975	Jul 16 05:14 PM
Maduck Sean	Chief Commercial Officer	Jul 13	Option Exercise	2.24	10,000	22,400	40,024	Jul 14 05:08 PM
Maduck Sean	Chief Commercial Officer	Jul 07	Option Exercise	3.29	25,000	82,250	55,024	Jul 09 05:29 PM
Maduck Sean	Chief Commercial Officer	Jul 07	Sale	22.19	25,000	554,692	30,024	Jul 09 05:29 PM
BAKER G LEONARD JR	Director	Jun 11	Buy	21.53	100,000	2,153,000	3,308,303	Jun 15 07:01 PM
BAKER G LEONARD JR	Director	Jun 11	Buy	21.53	50,000	1,076,500	1,046,838	Jun 15 07:01 PM
Swisher Daniel N JR	Director	Jun 02	Option Exercise	6.55	7,500	49,125	7,500	Jun 04 06:56 PM
Swisher Daniel N JR	Director	Jun 02	Sale	21.48	7,500	161,085	0	Jun 04 06:56 PM
BAKER G LEONARD JR	Director	May 18	Option Exercise	3.70	150,000	555,000	1,146,838	May 20 06:35 PM
MAHONEY DAVID L	Director	May 11	Option Exercise	4.42	30,000	132,600	118,984	May 13 05:40 PM
Robb Gary Charles	Chief Financial Officer	Apr 23	Sale	24.02	10,000	240,219	75,638	Apr 27 06:30 PM
WILSON JAMES N	Director	Apr 14	Option Exercise	4.42	200,000	884,000	200,000	Apr 16 09:08 PM
Swisher Daniel N JR	Director	Apr 05	Option Exercise	6.55	7,500	49,125	7,500	Apr 07 05:20 PM
Swisher Daniel N JR	Director	Apr 05	Sale	24.14	7,500	181,036	0	Apr 07 05:20 PM
Lyon Joseph Douglas	Chief Accounting Officer	Apr 01	Option Exercise	11.35	25,000	283,750	25,000	Apr 05 05:12 PM
Lyon Joseph Douglas	Chief Accounting Officer	Apr 01	Sale	23.88	25,000	597,030	0	Apr 05 05:12 PM
Lyon Joseph Douglas	Chief Accounting Officer	Mar 01	Option Exercise	8.27	25,000	206,750	25,000	Mar 03 05:38 PM
Lyon Joseph Douglas	Chief Accounting Officer	Mar 01	Sale	25.21	25,000	630,320	0	Mar 03 05:38 PM
Maduck Sean	See Remarks	Feb 16	Option Exercise	3.29	8,989	29,574	39,013	Feb 16 08:50 PM
Maduck Sean	See Remarks	Feb 16	Sale	28.25	8,989	253,903	30,024	Feb 16 08:50 PM
Robb Gary Charles	Chief Financial Officer	Feb 12	Sale	28.22	112,100	3,163,899	85,638	Feb 16 08:15 PM
Maduck Sean	See Remarks	Feb 11	Option Exercise	3.29	3,400	11,186	33,424	Feb 16 08:50 PM
Maduck Sean	See Remarks	Feb 11	Sale	29.78	3,400	101,249	30,024	Feb 16 08:50 PM
Robb Gary Charles	Chief Financial Officer	Feb 11	Sale	29.78	3,400	101,249	197,738	Feb 16 08:15 PM
Lyon Joseph Douglas	Chief Accounting Officer	Feb 03	Option Exercise	8.27	25,000	206,750	25,000	Feb 04 07:13 PM
Lyon Joseph Douglas	Chief Accounting Officer	Feb 03	Sale	29.18	25,000	729,570	0	Feb 04 07:13 PM
Robb Gary Charles	Chief Financial Officer	Jan 22	Option Exercise	2.70	451,852	1,220,000	459,877	Jan 26 09:35 PM
BELANOFF JOSEPH K	Chief Executive Officer	Jan 22	Option Exercise	4.42	800,000	3,536,000	3,299,214	Jan 26 09:33 PM
Swisher Daniel N JR	Director	Jan 19	Option Exercise	6.55	5,000	32,750	5,000	Jan 21 05:05 PM
Swisher Daniel N JR	Director	Jan 19	Sale	28.74	5,000	143,686	0	Jan 21 05:05 PM
Lyon Joseph Douglas	Chief Accounting Officer	Jan 04	Option Exercise	8.27	25,000	206,750	25,000	Jan 04 07:43 PM
Lyon Joseph Douglas	Chief Accounting Officer	Jan 04	Sale	26.13	25,000	653,345	0	Jan 04 07:43 PM
Lyon Joseph Douglas	Chief Accounting Officer	Dec 30	Option Exercise	7.54	25,000	188,457	25,000	Jan 04 07:43 PM
Lyon Joseph Douglas	Chief Accounting Officer	Dec 30	Sale	26.07	25,000	651,752	0	Jan 04 07:43 PM
BAKER G LEONARD JR	Director	Dec 01	Buy	22.64	68	1,540	3,208,303	Dec 02 07:41 PM
BAKER G LEONARD JR	Director	Nov 30	Buy	22.80	1,109	25,285	3,208,235	Dec 02 07:41 PM
BAKER G LEONARD JR	Director	Nov 25	Buy	22.81	361	8,233	3,207,126	Nov 30 07:46 PM
Hunt Hazel	Chief Scientific Officer	Nov 24	Option Exercise	3.96	50,000	198,000	50,200	Nov 27 04:08 PM
BAKER G LEONARD JR	Director	Nov 24	Buy	22.93	1,429	32,766	3,206,765	Nov 24 08:06 PM
BAKER G LEONARD JR	Director	Nov 23	Buy	22.93	1,551	35,562	3,205,336	Nov 24 08:06 PM
BAKER G LEONARD JR	Director	Nov 18	Buy	17.91	2,372	42,491	3,203,785	Nov 19 07:48 PM
BAKER G LEONARD JR	Director	Nov 17	Buy	17.82	7,883	140,469	3,201,413	Nov 17 07:43 PM
BAKER G LEONARD JR	Director	Nov 13	Buy	17.94	200	3,588	3,193,530	Nov 17 07:43 PM
BAKER G LEONARD JR	Director	Nov 10	Buy	17.71	15,000	265,635	3,193,330	Nov 12 06:07 PM
BAKER G LEONARD JR	Director	Nov 09	Buy	17.96	3,786	68,013	3,178,330	Nov 12 06:07 PM
BAKER G LEONARD JR	Director	Nov 06	Buy	17.98	13,500	242,665	3,174,544	Nov 10 08:21 PM
Swisher Daniel N JR	Director	Oct 19	Option Exercise	6.55	5,000	32,750	5,000	Oct 21 09:08 PM
Swisher Daniel N JR	Director	Oct 19	Sale	17.66	5,000	88,301	0	Oct 21 09:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience